000810068 001__ 810068
000810068 005__ 20210129223256.0
000810068 0247_ $$2doi$$a10.1016/j.ejps.2016.04.016
000810068 0247_ $$2ISSN$$a0928-0987
000810068 0247_ $$2ISSN$$a1879-0720
000810068 0247_ $$2WOS$$aWOS:000376655600004
000810068 0247_ $$2altmetric$$aaltmetric:6777911
000810068 0247_ $$2pmid$$apmid:27086111
000810068 037__ $$aFZJ-2016-02949
000810068 082__ $$a610
000810068 1001_ $$0P:(DE-HGF)0$$aLeithold, Leonie H. E.$$b0
000810068 245__ $$aPharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease
000810068 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2016
000810068 3367_ $$2DRIVER$$aarticle
000810068 3367_ $$2DataCite$$aOutput Types/Journal article
000810068 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1465371126_20099
000810068 3367_ $$2BibTeX$$aARTICLE
000810068 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000810068 3367_ $$00$$2EndNote$$aJournal Article
000810068 520__ $$aPeptides are more and more considered for the development of drug candidates. However, they frequently exhibit severe disadvantages such as instability and unfavourable pharmacokinetic properties. Many peptides are rapidly cleared from the organism and oral bioavailabilities as well as in vivo half-lives often remain low. In contrast, some peptides consisting solely of d-enantiomeric amino acid residues were shown to combine promising therapeutic properties with high proteolytic stability and enhanced pharmacokinetic parameters. Recently, we have shown that D3 and RD2 have highly advantageous pharmacokinetic properties. Especially D3 has already proven promising properties suitable for treatment of Alzheimer's disease. Here, we analyse the pharmacokinetic profiles of D3D3 and RD2D3, which are head-to-tail tandem d-peptides built of D3 and its derivative RD2. Both D3D3 and RD2D3 show proteolytic stability in mouse plasma and organ homogenates for at least 24 h and in murine and human liver microsomes for 4 h. Notwithstanding their high affinity to plasma proteins, both peptides are taken up into the brain following i.v. as well as i.p. administration. Although both peptides contain identical d-amino acid residues, they are arranged in a different sequence order and the peptides show differences in pharmacokinetic properties. After i.p. administration RD2D3 exhibits lower plasma clearance and higher bioavailability than D3D3. We therefore concluded that the amino acid sequence of RD2 leads to more favourable pharmacokinetic properties within the tandem peptide, which underlines the importance of particular sequence motifs, even in short peptides, for the design of further therapeutic d-peptides.
000810068 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000810068 588__ $$aDataset connected to CrossRef
000810068 7001_ $$0P:(DE-Juel1)145884$$aJiang, Nan$$b1
000810068 7001_ $$0P:(DE-Juel1)164337$$aPost, Julia$$b2
000810068 7001_ $$0P:(DE-Juel1)142279$$aNiemietz, Nicole$$b3
000810068 7001_ $$0P:(DE-Juel1)166069$$aSchartmann, Elena$$b4
000810068 7001_ $$0P:(DE-Juel1)162487$$aZiehm, Tamar$$b5
000810068 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b6
000810068 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b7
000810068 7001_ $$0P:(DE-HGF)0$$aBreitkreutz, Jörg$$b8
000810068 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b9
000810068 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b10
000810068 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b11$$eCorresponding author$$ufzj
000810068 773__ $$0PERI:(DE-600)1483522-8$$a10.1016/j.ejps.2016.04.016$$gVol. 89, p. 31 - 38$$p31 - 38$$tEuropean journal of pharmaceutical sciences$$v89$$x0928-0987$$y2016
000810068 8564_ $$uhttps://juser.fz-juelich.de/record/810068/files/1-s2.0-S0928098716301191-main.pdf$$yRestricted
000810068 8564_ $$uhttps://juser.fz-juelich.de/record/810068/files/1-s2.0-S0928098716301191-main.gif?subformat=icon$$xicon$$yRestricted
000810068 8564_ $$uhttps://juser.fz-juelich.de/record/810068/files/1-s2.0-S0928098716301191-main.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000810068 8564_ $$uhttps://juser.fz-juelich.de/record/810068/files/1-s2.0-S0928098716301191-main.jpg?subformat=icon-180$$xicon-180$$yRestricted
000810068 8564_ $$uhttps://juser.fz-juelich.de/record/810068/files/1-s2.0-S0928098716301191-main.jpg?subformat=icon-640$$xicon-640$$yRestricted
000810068 8564_ $$uhttps://juser.fz-juelich.de/record/810068/files/1-s2.0-S0928098716301191-main.pdf?subformat=pdfa$$xpdfa$$yRestricted
000810068 909CO $$ooai:juser.fz-juelich.de:810068$$pVDB
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b0$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145884$$aForschungszentrum Jülich$$b1$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164337$$aForschungszentrum Jülich$$b2$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)142279$$aForschungszentrum Jülich$$b3$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166069$$aForschungszentrum Jülich$$b4$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162487$$aForschungszentrum Jülich$$b5$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b6$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b7$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b9$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b10$$kFZJ
000810068 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b11$$kFZJ
000810068 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000810068 9141_ $$y2016
000810068 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000810068 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000810068 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J PHARM SCI : 2014
000810068 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000810068 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000810068 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000810068 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000810068 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000810068 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000810068 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000810068 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000810068 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000810068 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000810068 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000810068 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x1
000810068 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x2
000810068 980__ $$ajournal
000810068 980__ $$aVDB
000810068 980__ $$aUNRESTRICTED
000810068 980__ $$aI:(DE-Juel1)INM-4-20090406
000810068 980__ $$aI:(DE-Juel1)ICS-6-20110106
000810068 980__ $$aI:(DE-82)080010_20140620
000810068 981__ $$aI:(DE-Juel1)IBI-7-20200312
000810068 981__ $$aI:(DE-Juel1)ICS-6-20110106